<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002832</url>
  </required_header>
  <id_info>
    <org_study_id>DM94-077</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-94077</secondary_id>
    <secondary_id>NCI-G96-1000</secondary_id>
    <secondary_id>CDR0000065034</secondary_id>
    <nct_id>NCT00002832</nct_id>
  </id_info>
  <brief_title>Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia</brief_title>
  <official_title>Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be an effective treatment for leukemia,
      myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed following bone
      marrow transplantation.

      PURPOSE: Phase I/II trial to study the effectiveness of decitabine and peripheral stem cell
      transplantation in treating patients who have leukemia, myelodysplastic syndrome, or chronic
      myelogenous leukemia that has relapsed after bone marrow transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of decitabine in patients with relapse
      post allogenic bone marrow transplant. II. Determine the toxicity of decitabine combined with
      filgrastim (G-CSF) primed allogeneic peripheral blood stem cells in patients who relapsed
      within 1 year after allogeneic bone marrow transplantation. III. Determine the effectiveness
      in reinducing remission in these patients.

      OUTLINE: Patients receive decitabine IV for 6 hours every 12 hr for 5 days. Peripheral blood
      stem cells (PBSC) are administered 5 days after last dose of decitabine. Donors receive
      filgrastim subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC
      collection. If insufficient number of cells are collected, bone marrow can be harvested for
      supplementation. Donor cells should be collected prior to decitabine infusion. Patients
      receive filgrastim SQ administered daily starting 1 day after PBSC infusion until blood
      counts recover. For GVHD prophylaxis, patients receive cyclosporine IV daily on day -2, then
      orally once dose is tolerable. Dose of decitabine is escalated in cohorts of 3-6 patients. If
      dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then that dose is
      declared the maximum tolerated dose. Patients are followed weekly. If none of the first 5
      patients survive in remission for more than 100 days, the study will be terminated.

      PROJECTED ACCRUAL: At least 15 patients will be accrued for this study over 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) Decitabine</measure>
    <time_frame>Weekly for 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.</description>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <other_name>C-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>IV daily on day -2, then orally once dose is tolerable, dose may be escalated.</description>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <other_name>Sandimmune</other_name>
    <other_name>CYA</other_name>
    <other_name>Cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>IV for 6 hours every 12 hr for 5 days.</description>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <other_name>ASCT</other_name>
    <other_name>Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.</description>
    <arm_group_label>Decitabine + Stem Cell Transplantation</arm_group_label>
    <other_name>PBSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute leukemia, myelodysplastic syndromes or chronic myelogenous
        leukemia (CML) in accelerated phase or blast crisis and relapsed within 1 year after
        allogeneic bone marrow transplantation Must not be candidates for second course of high
        dose chemoradiotherapy

        PATIENT CHARACTERISTICS: Age: 60 and under Performance status: Zubrod 0-2 Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3 mg/dL Renal:
        Creatinine less than 2 mg/dL Cardiovascular: Greater than 40% ejection fraction per MUGA
        scan or ECHO Other: Not pregnant No serious intercurrent illness No active CNS disease Must
        be ineligible for protocols of higher priority No active acute graft vs host disease (GVHD)
        greater than grade 2 or extensive chronic GVHD No active uncontrolled infection Original
        marrow donor must undergo filgrastim primed peripheral blood stem cell collection

        PRIOR CONCURRENT THERAPY: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Giralt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decitabine</keyword>
  <keyword>Dacogen</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Sandimmune</keyword>
  <keyword>CYA</keyword>
  <keyword>Cyclosporin A</keyword>
  <keyword>Peripheral blood stem cells</keyword>
  <keyword>PBSC</keyword>
  <keyword>Allogeneic bone marrow transplantation</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

